Parkinson's disease: from monogenic forms to genetic susceptibility factors

scientific article

Parkinson's disease: from monogenic forms to genetic susceptibility factors is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1093/HMG/DDP012
P3181OpenCitations bibliographic resource ID1561676
P698PubMed publication ID19297401
P5875ResearchGate publication ID24211343

P2093author name stringA. Brice
S. Lesage
P2860cites workInterface between tauopathies and synucleinopathies: A tale of two proteinsQ22252940
High-resolution whole-genome association study of Parkinson disease.Q24535861
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodiesQ24653247
Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson diseaseQ24656075
Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36Q24680678
Mutation in the alpha-synuclein gene identified in families with Parkinson's diseaseQ27860459
alpha-Synuclein locus triplication causes Parkinson's diseaseQ27860533
Alpha-synuclein in Lewy bodiesQ27860680
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPaseQ28116395
Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant miceQ28208193
Glucocerebrosidase mutations in subjects with parkinsonismQ28239212
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplicationsQ28241852
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's diseaseQ28257086
Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signalingQ28505191
Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in miceQ28507648
Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of dataQ28943545
The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese populationQ46619827
Essential tremor and the common LRRK2 G2385R variantQ46721342
Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy.Q46854860
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian populationQ46943278
Importance of low-range CAG expansion and CAA interruption in SCA2 ParkinsonismQ46960409
Neuropathology provides clues to the pathophysiology of Gaucher diseaseQ47247270
The parkinsonian phenotype of spinocerebellar ataxia type 2.Q47254835
Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patientsQ47587717
Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutationQ48109654
Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian populationQ48266604
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplicationQ48298527
Frequency of LRRK2 mutations in early- and late-onset Parkinson diseaseQ48392751
Glucocerebrosidase mutations are an important risk factor for Lewy body disordersQ48491146
Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlationQ48784105
Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's diseaseQ50280082
The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease.Q51731132
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.Q53249928
alpha-Synuclein gene duplication is present in sporadic Parkinson disease.Q53473267
Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease.Q53532682
Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplicationQ46318649
Lrrk2 R1628P in non-Chinese Asian racesQ46439311
Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanismsQ46583182
Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutationQ46587417
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementiaQ29547174
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's diseaseQ29547175
Alpha-synuclein locus duplication as a cause of familial Parkinson's diseaseQ29614762
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyQ29614953
Lack of replication of association between GIGYF2 variants and Parkinson disease.Q30437358
Genomewide association study for susceptibility genes contributing to familial Parkinson diseaseQ30437480
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD studyQ30440660
Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controlsQ30440991
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson diseaseQ30483458
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2).Q30938617
Multiple regions of alpha-synuclein are associated with Parkinson's diseaseQ31155710
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*.Q33226010
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic dataQ33226682
A common genetic factor for Parkinson disease in ethnic Chinese population in TaiwanQ33267533
Meta-analysis in genome-wide association datasets: strategies and application in Parkinson diseaseQ33276409
Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathwayQ33314917
Analysis of the LRRK2 Gly2385Arg variant in primary dystonia and multiple system atrophy in TaiwanQ33331261
LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patientsQ33340326
Neither replication nor simulation supports a role for the axon guidance pathway in the genetics of Parkinson's diseaseQ33352050
Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3.Q33377437
Glucocerebrosidase gene mutations: a risk factor for Lewy body disordersQ33677320
Significant linkage of Parkinson disease to chromosome 2q36-37Q33904993
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populationsQ33942173
CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphismsQ34100075
SCA2 may present as levodopa-responsive parkinsonismQ34187852
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi JewsQ34365028
A susceptibility locus for Parkinson's disease maps to chromosome 2p13.Q34460129
Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's diseaseQ34565111
PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain ironQ34568479
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson diseaseQ34626200
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?Q34701291
Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and ParkinQ34892238
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.Q35070498
Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogenQ35117445
Present and future drug treatment for Parkinson's diseaseQ35484805
Growth hormone treatment in short Japanese children born small for gestational age.Q35946649
Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among TaiwaneseQ36227499
How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the diseaseQ36310520
Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arraysQ36719174
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutationsQ36748778
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson diseaseQ36761674
Deciphering the role of heterozygous mutations in genes associated with parkinsonismQ36854642
Genetic variation of Omi/HtrA2 and Parkinson's diseaseQ37037500
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's diseaseQ37054679
The utility F-box for protein destructionQ37111318
Non-motor symptoms in Parkinson's diseaseQ37114116
Neurodegeneration associated with genetic defects in phospholipase A(2).Q37179015
Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutationsQ37361830
Genomic investigation of alpha-synuclein multiplication and parkinsonismQ37362778
Genetic anticipation in Parkinson's diseaseQ38509730
Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjectsQ38938687
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic studyQ39086510
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease familiesQ39095724
Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?Q39171885
G2019S LRRK2 mutation in French and North African families with Parkinson's diseaseQ39171895
A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's diseaseQ39579467
The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.Q40074115
Analysis of Lrrk2 R1628P as a risk factor for Parkinson's diseaseQ40102731
LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland ChinaQ40133563
Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2.Q40210208
The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.Q40223841
Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in AsiaQ40251831
Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter systemQ40761847
Neuropathology of Parkinson's diseaseQ41095404
Considerations for genomewide association studies in Parkinson diseaseQ42418603
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's diseaseQ42628290
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's diseaseQ42675021
The LRRK2 gene in Parkinson's disease: mutation screening in patients from GermanyQ42765219
LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th centuryQ43004241
The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients.Q43560873
Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patientsQ44009968
Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's diseaseQ44286639
The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's diseaseQ44594403
New genetic insights into Parkinson's diseaseQ45138677
Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 familiesQ45219624
Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson diseaseQ46233748
Novel ATP13A2 variant associated with Parkinson disease in Taiwan and SingaporeQ46241226
Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: clinical implications.Q53610557
Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia.Q54537164
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease.Q54626622
LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.Q54697490
alpha-Synuclein promoter confers susceptibility to Parkinson's disease.Q54699461
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.Q55041570
Alpha-synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patientsQ56637598
PARK9-LINKED PARKINSONISM IN EASTERN ASIA: MUTATION DETECTION IN ATP13A2 AND CLINICAL PHENOTYPEQ56772080
Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarianQ57248434
A susceptibility gene for late-onset idiopathic Parkinson's diseaseQ57309530
Analysis of the glucocerebrosidase gene in Parkinson's diseaseQ57318911
The Ala53Thr mutation in the α-synuclein gene in a Korean family with Parkinson diseaseQ57577939
Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson diseaseQ57623825
Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease familiesQ57629162
alpha-synuclein gene haplotypes are associated with Parkinson's diseaseQ57905836
Are interruptedSCA2CAG repeat expansions responsible for parkinsonism?Q57970884
Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson DiseaseQ57977634
LRRK2 mutation in familial Parkinson’s disease in a Taiwanese population: clinical, PET, and functional studiesQ57983248
-Synuclein, pesticides, and Parkinson disease: A case-control studyQ57983254
LRRK2 mutations in Parkinson diseaseQ57983290
Lrrk2 pathogenic substitutions in Parkinson's diseaseQ57983291
LRRK2G2019S as a Cause of Parkinson's Disease in North African ArabsQ58489573
A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's diseaseQ58870346
Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr ?-synuclein mutationQ59544661
Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonismQ60532601
Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson diseaseQ62128619
Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's diseaseQ62588920
Re: Alpha-synuclein gene duplication is present in sporadic Parkinson diseaseQ64913752
LRRK2 R1628P increases risk of Parkinson's disease: replication evidenceQ64958593
Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variantsQ79555494
Neurological signs: Behçet's disease, coeliac disease, both, or neither?Q79652541
Comparing LRRK2 Gly2385Arg carriers with noncarriersQ79751589
Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementiaQ80493033
Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controlsQ80535570
Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese AsiansQ80691674
Causal relation between alpha-synuclein gene duplication and familial Parkinson's diseaseQ80794093
Association between Parkinson's disease and glucocerebrosidase mutations in BrazilQ80806938
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onsetQ81147302
The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's diseaseQ81322451
Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onsetQ81403790
The glucocerebrosidase gene and Parkinson's disease in Ashkenazi JewsQ81411336
The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's diseaseQ81415949
Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's diseaseQ82704418
A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in TaiwanQ83191880
Genetic analysis of SCA2, 3 and 17 in idiopathic Parkinson's diseaseQ83315441
Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's diseaseQ83941112
???Q64913750
P433issueR1
P407language of work or nameEnglishQ1860
P921main subjectParkinson's diseaseQ11085
P304page(s)R48-R59
P577publication date2009-04-15
P1433published inHuman Molecular GeneticsQ2720965
P1476titleParkinson's disease: from monogenic forms to genetic susceptibility factors
P478volume18

Reverse relations

cites work (P2860)
Q36223954(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
Q384500331-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease in zebrafish
Q37620482A dual-hit animal model for age-related parkinsonism
Q34801743A genome-wide linkage screen in the Amish with Parkinson disease points to chromosome 6
Q52322083A meta-analysis of public microarray data identifies biological regulatory networks in Parkinson's disease.
Q37655091A network view on Parkinson's disease
Q36020336A reference library of peripheral blood mononuclear cells for SWATH-MS analysis
Q38850614A53T in a parkinsonian family: a clinical update of the SNCA phenotypes
Q28119120ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons
Q39516168ATP13A2 variability in Taiwanese Parkinson's disease
Q37607449Abnormal mitochondrial dynamics and neurodegenerative diseases
Q37779272Achalasia: will genetic studies provide insights?
Q39355888Acute exposure to a Mn/Zn ethylene-bis-dithiocarbamate fungicide leads to mitochondrial dysfunction and increased reactive oxygen species production in Caenorhabditis elegans
Q55667027Adipose-derived Stem Cells Stimulated with n-Butylidenephthalide Exhibit Therapeutic Effects in a Mouse Model of Parkinson's Disease.
Q64768798Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA)
Q38792540Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity
Q93050900Allopregnanolone Modulates GABAAR-Dependent CaMKIIδ3 and BDNF to Protect SH-SY5Y Cells Against 6-OHDA-Induced Damage
Q64764558Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease
Q49045276Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro
Q37066475An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome
Q34800195An overview on the correlation of neurological disorders with cardiovascular disease
Q33911698Analysis of Dosage Mutation in PARK2 among Korean Patients with Early-Onset or Familial Parkinson's Disease
Q37271108Analysis of LRRK2, SNCA, and ITGA8 Gene Variants with Sporadic Parkinson's Disease Susceptibility in Chinese Han Population.
Q34992975Analysis of Thr12Met and Ala1144Thr mutations of the ATP13A2 gene in Parkinson's disease patients in Xinjiang Uygur and Han ethnic groups
Q82253370Analysis of exon dosage using MLPA in South African Parkinson's disease patients
Q26799331Applications of Induced Pluripotent Stem Cells in Studying the Neurodegenerative Diseases
Q37598121Are there common biochemical and molecular mechanisms controlling manganism and parkisonism
Q37424589Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis
Q38049356Association of catechol-o-methyltransferase polymorphism (Val108/158Met) with Parkinson's disease: a meta-analysis
Q40201296Association of four new candidate genetic variants with Parkinson's disease in a Han Chinese population
Q35935522Association of three candidate genetic variants in RAB7L1/NUCKS1, MCCC1 and STK39 with sporadic Parkinson's disease in Han Chinese
Q37645620Association studies of sporadic Parkinson's disease in the genomic era.
Q47915648Associations of specific psychiatric disorders with isolated focal dystonia, and monogenic and idiopathic Parkinson's disease
Q46283192Astragaloside IV attenuates the H2O2-induced apoptosis of neuronal cells by inhibiting α-synuclein expression via the p38 MAPK pathway
Q38018827Autoimmunity, dendritic cells and relevance for Parkinson's disease
Q39454262Autophagy and Human Neurodegenerative Diseases-A Fly's Perspective
Q28273228Autophagy in Neurodegenerative Diseases and Metal Neurotoxicity
Q38164897Autophagy in inflammation, infection, neurodegeneration and cancer
Q37800102Autosomal Recessive Mutations in the Development of Parkinson‘s Disease
Q38642565Back and forth in time: Directing age in iPSC-derived lineages.
Q38203487Barcoding heat shock proteins to human diseases: looking beyond the heat shock response
Q38093247Biomarkers for the diagnosis and management of Parkinson's disease
Q50695868Biomarkers in Parkinson's disease.
Q36616565COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease prog
Q42534539Calcium homeostasis in aging neurons
Q38208179Calcium signaling in Parkinson's disease.
Q37085692Calpastatin gene (CAST) is not associated with late onset sporadic Parkinson's disease in the Han Chinese population
Q35875886Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration
Q28080770Cell reprogramming and neuronal differentiation applied to neurodegenerative diseases: Focus on Parkinson's disease
Q93138854Cell therapy for Parkinson's disease is coming of age: current challenges and future prospects with a focus on immunomodulation
Q38021569Cellular and molecular mechanisms of antioxidants in Parkinson's disease
Q90714057Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson's disease
Q38553329Chaperone-mediated autophagy and neurodegeneration: connections, mechanisms, and therapeutic implications
Q35795120Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants
Q41996686Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation.
Q41863382Classification of Parkinson's Disease Genotypes in Drosophila Using Spatiotemporal Profiling of Vision
Q64929400Combined accelerometer and genetic analysis to differentiate essential tremor from Parkinson's disease.
Q36613610Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease
Q34409499Concise review: Patient-derived olfactory stem cells: new models for brain diseases
Q35234940Construction and analysis of the protein-protein interaction networks based on gene expression profiles of Parkinson's disease
Q37970303Control of autophagy as a therapy for neurodegenerative disease
Q23914777Correlation between the biochemical pathways altered by mutated Parkinson-related genes and chronic exposure to manganese
Q36533944Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide
Q38433683DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease
Q27312297DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient
Q35290033Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease
Q44617144Decreased expression of lysosomal alpha-galactosiase A gene in sporadic Parkinson's disease.
Q36020884Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations
Q36025246Development of stem cell-based therapy for Parkinson's disease
Q64104013Differentiation of adult human retinal pigment epithelial cells into dopaminergic-like cells in vitro and in the recipient monkey brain
Q41964090Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.
Q29248297Disease-toxicant interactions in Parkinson's disease neuropathology
Q33940936Disruption of LRRK2 does not cause specific loss of dopaminergic neurons in zebrafish
Q61449551Distinct Stress Response and Altered Striatal Transcriptome in Alpha-Synuclein Overexpressing Mice
Q38067885Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?
Q36002833Dopamine-derived quinones affect the structure of the redox sensor DJ-1 through modifications at Cys-106 and Cys-53
Q41117800Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects
Q36680414Drug discovery in Parkinson's disease-Update and developments in the use of cellular models
Q28073686Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases
Q41317700Early Onset Parkinson's Disease in a family of Moroccan origin caused by a p.A217D mutation in PINK1: a case report
Q58582532Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction
Q42723659Effects of balance and gait training on the recovery of the motor function in an animal model of Parkinson's disease
Q43577652Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9.
Q38598842Emerging bioinformatics approaches for analysis of NGS-derived coding and non-coding RNAs in neurodegenerative diseases.
Q37654778Emerging roles of Wnts in the adult nervous system
Q37926552Emerging roles of epigenetic mechanisms in Parkinson's disease
Q38502761Emotional dysfunctions in neurodegenerative diseases.
Q24293694Endoplasmic reticulum stress and Parkinson's disease: the role of HRD1 in averting apoptosis in neurodegenerative disease
Q24630696Enhancing CNS repair in neurological disease: challenges arising from neurodegeneration and rewiring of the network
Q28074723Environmental Exposures and Parkinson's Disease
Q92316611Evaluation of the Common Molecular Basis in Alzheimer's and Parkinson's Diseases
Q39214168Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study
Q35668490Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus
Q55617564Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy.
Q38079242Exosomes-associated neurodegeneration and progression of Parkinson's disease
Q37809870Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities
Q39428788Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
Q33955534Familial associations of Alzheimer disease and essential tremor with Parkinson disease
Q30995743Family-based genome scan for age at onset of late-onset Alzheimer's disease in whole exome sequencing data
Q35846517Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples
Q36745293Focusing brain therapeutic interventions in space and time for Parkinson's disease
Q23920397From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure
Q37578490Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease
Q36777244GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.
Q37979978Gaucher disease and the synucleinopathies: refining the relationship
Q35851610Gaucher-Associated Parkinsonism
Q28388674Gene-environment interactions: key to unraveling the mystery of Parkinson's disease
Q36050210Genetic Mutation Analysis of Parkinson's Disease Patients Using Multigene Next-Generation Sequencing Panels.
Q26768278Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease
Q38637878Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review
Q35712293Genetic Variants of SNCA Are Associated with Susceptibility to Parkinson's Disease but Not Amyotrophic Lateral Sclerosis or Multiple System Atrophy in a Chinese Population
Q34996445Genetic analysis of the FBXO42 gene in Chinese Han patients with Parkinson's disease
Q34234597Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome
Q37328854Genetic association of NOS1 exon18, NOS1 exon29, ABCB1 1236C/T, and ABCB1 3435C/T polymorphisms with the risk of Parkinson's disease: A meta-analysis
Q44358768Genetic bases and phenotypes of autosomal recessive Parkinson disease in a Turkish population
Q94586186Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis
Q94465937Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells
Q39253264Genetic risk for Parkinson's disease correlates with alterations in neuronal manganese sensitivity between two human subjects
Q27022109Genetics of Parkinson's disease - a clinical perspective
Q34898429Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling
Q58764784Genome Editing of Pigs for Agriculture and Biomedicine
Q84485275Genome-wide association studies: the key to unlocking neurodegeneration?
Q24596763Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease
Q51620290Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.
Q33991709Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes
Q36513434Glucocerebrosidase L444P mutation confers genetic risk for Parkinson's disease in central China
Q43823053HLA-DRA is associated with Parkinson's disease in Iranian population.
Q92448054Han Chinese family with early-onset Parkinson's disease carries novel compound heterozygous mutations in the PARK2 gene
Q43215480Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications
Q35675965Heritability of Parkinson disease in Swedish twins: a longitudinal study
Q50254943High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease.
Q40658284High-resolution arrays reveal burden of copy number variations on Parkinson disease genes associated with increased disease risk in random cohorts
Q43921081How parkinsonism influences life: the patients' point of view
Q38168763Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development
Q38503340Identification of Parkinson's disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson's disease patients
Q34279026Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation
Q28743569Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease
Q34449994Identification of key pathways and transcription factors related to Parkinson disease in genome wide
Q38184645Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders
Q30397945In Silico Analysis of SNPs in PARK2 and PINK1 Genes That Potentially Cause Autosomal Recessive Parkinson Disease.
Q24655848Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein
Q35812803Increased Transcript Complexity in Genes Associated with Chronic Obstructive Pulmonary Disease
Q38737027Induced pluripotent stem cell-based modeling of neurodegenerative diseases: a focus on autophagy.
Q26771402Induced pluripotent stem cells for modeling neurological disorders
Q35687315Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons
Q55497257Integrated Analysis and Identification of Novel Biomarkers in Parkinson's Disease.
Q35899904Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease
Q36116735Intelligence: shared genetic basis between Mendelian disorders and a polygenic trait
Q36489290Interaction between RING1 (R1) and the Ubiquitin-like (UBL) Domains Is Critical for the Regulation of Parkin Activity
Q37577611Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease.
Q35585714Interleukin-1 receptor antagonist reduces neonatal lipopolysaccharide-induced long-lasting neurobehavioral deficits and dopaminergic neuronal injury in adult rats
Q38103856Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?
Q38817063Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
Q34093439Iron transport in Parkinson's disease
Q35158376Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?
Q41577935Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH).
Q34145889L10p and P158DEL DJ‐1 mutations cause protein instability, aggregation, and dimerization impairments
Q64791386LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease
Q42873469LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß.
Q33603103LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients
Q42927984LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity
Q26861279LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease
Q24307455LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study
Q24301357LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1
Q38389768Lack of association between the ATP13A2 A746T variant and Parkinson's disease susceptibility in Han Chinese: a meta-analysis
Q35754683Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease
Q55240777Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.
Q88643636Long Non-Coding RNAs in Multifactorial Diseases: Another Layer of Complexity
Q28109404Manganese Homeostasis and Transport
Q36223221Manganese-induced toxicity in normal and human B lymphocyte cell lines containing a homozygous mutation in parkin.
Q39465478Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease
Q28394732Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease
Q37043326Membrane trafficking in neuronal maintenance and degeneration.
Q37090660Mendelian Randomization - the Key to Understanding Aspects of Parkinson's Disease Causation?
Q53245195Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease.
Q36128123Meta-Analysis of Parkinson's Disease Transcriptome Data Using TRAM Software: Whole Substantia Nigra Tissue and Single Dopamine Neuron Differential Gene Expression.
Q38109630Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures
Q47102033MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease.
Q36640417Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein
Q89462541Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice
Q34292484Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts
Q90457655Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases
Q37889815Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease
Q28280353Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease
Q38237889Mitochondrial dynamic changes in health and genetic diseases
Q36365785Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders
Q37587126Mitophagy and Parkinson's disease: the PINK1-parkin link.
Q60919555Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells
Q38005912Modeling Parkinson's disease using induced pluripotent stem cells
Q58114516Models of Sporadic Parkinson's Disease
Q34014651Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent
Q36872325Modulating the Amyloidogenesis of α-Synuclein
Q37749063Molecular mechanisms of pathogenesis of Parkinson's disease.
Q37968084Molecular pathways in sporadic PD.
Q37679384Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease
Q34100399Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review
Q38112215Network modeling to identify new mechanisms and therapeutic targets for Parkinson's disease
Q27021719Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases
Q58737028Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
Q37668234Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms
Q90359231Neurodegenerative diseases: model organisms, pathology and autophagy
Q37538771Neurodegenerative disorders and nanoformulated drug development
Q34234625Neuroimaging: current role in detecting pre-motor Parkinson's disease.
Q26765693Neuroprotective Transcription Factors in Animal Models of Parkinson Disease
Q36333141Neurosupportive Role of Vanillin, a Natural Phenolic Compound, on Rotenone Induced Neurotoxicity in SH-SY5Y Neuroblastoma Cells
Q37951958New animal models of Parkinson's disease
Q38430373New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation
Q38263132No evidence of association between common European mitochondrial DNA variants in Alzheimer, Parkinson, and migraine in the Spanish population
Q47805564No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs.
Q35544534Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria.
Q36732766Nrf2--a therapeutic target for the treatment of neurodegenerative diseases
Q57073168Nucleolar Disruption in Dopaminergic Neurons Leads to Oxidative Damage and Parkinsonism through Repression of Mammalian Target of Rapamycin Signaling
Q36560195One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system
Q37509229Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle
Q47102647PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway.
Q42183671ParkDB: a Parkinson's disease gene expression database
Q37337917Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation
Q27340039Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease
Q34719767Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease
Q37972057Parkin: much more than a simple ubiquitin ligase
Q52559939Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process.
Q39714333Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells.
Q42562656Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?
Q34245014Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the nucleolus and sequestration into cytoplasmic aggregates via TRAF6
Q30438194Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance
Q37633575Parkinson's disease, autoimmunity, and olfaction
Q34140428Parkinson's disease: Exit toxins, enter genetics
Q52709039Parkinson's disease: Role of genetic and environment factors. Involvement in everyday clinical practice
Q33871291Parkinson's disease: insights from pathways
Q92155477Peroxiredoxin 5 Silencing Sensitizes Dopaminergic Neuronal Cells to Rotenone via DNA Damage-Triggered ATM/p53/PUMA Signaling-Mediated Apoptosis
Q37957393Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease
Q34181728Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease
Q36120753Phenome-based gene discovery provides information about Parkinson's disease drug targets
Q42338923Phenotypic Discordance in Siblings with Identical Compound Heterozygous PARK2 Mutations
Q48246699Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease
Q54603565Phylogenetic and in silico structural analysis of the Parkinson disease-related kinase PINK1.
Q36891717Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
Q27322563Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease.
Q37129378Potential Role of Caffeine in the Treatment of Parkinson's Disease
Q38629277Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease
Q47322162Predicting phenotypes from microarrays using amplified, initially marginal, eigenvector regression
Q36444517Premotor biomarkers for Parkinson's disease - a promising direction of research
Q64082784Prioritizing Parkinson's disease genes using population-scale transcriptomic data
Q37717607Progressive degeneration of dopaminergic neurons through TRP channel-induced cell death.
Q38091029Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis.
Q35080559Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes
Q39639654Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis
Q26800109Psychological Benefits of Nonpharmacological Methods Aimed for Improving Balance in Parkinson's Disease: A Systematic Review
Q34189660Recent advances in the genetics of Parkinson's disease
Q42239663Redox regulation of cysteine-dependent enzymes in neurodegeneration
Q26751786Research in Parkinson's disease in India: A review
Q56558187Restoration of motor control and dopaminergic activity in rats with unilateral 6-hydroxy-dopamine lesions
Q43375939Resveratrol Modulation of Protein Expression in parkin-Mutant Human Skin Fibroblasts: A Proteomic Approach
Q37844489Revisiting Mendelian disorders through exome sequencing
Q38659590Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.
Q38805953Role of Endoplasmic Reticulum Stress and Unfolded Protein Responses in Health and Diseases
Q34240463Role of mendelian genes in "sporadic" Parkinson's disease
Q36001692Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson's Disease
Q35859538SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population
Q57983208SNCA,MAPT, andGSK3Bin Parkinson disease: a gene-gene interaction study
Q37779808Safinamide in the treatment of Parkinson's disease
Q38899693Salsolinol Damaged Neuroblastoma SH-SY5Y Cells Induce Proliferation of Human Monocyte THP-1 Cells Through the mTOR Pathway in a Co-culture System
Q50167571Selective dopaminergic neurotoxicity of three heterocyclic amine subclasses in primary rat midbrain neurons.
Q38199451Selenium and selenoprotein function in brain disorders
Q52313428Self-administration of methamphetamine alters gut biomarkers of toxicity.
Q56381130Sex-Specific Transcriptome Differences in Substantia Nigra Tissue: A Meta-Analysis of Parkinson's Disease Data
Q58784650Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders
Q33666819Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene
Q46047010Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease
Q38657861Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons
Q46242053Stearic acid supplementation in high protein to carbohydrate (P:C) ratio diet improves physiological and mitochondrial functions of Drosophila melanogaster parkin null mutants
Q45143202Structural and functional in silico analysis of LRRK2 missense substitutions
Q33701172Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease
Q35682515Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice.
Q27026829Synaptic dysfunction and septin protein family members in neurodegenerative diseases
Q37802464Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy?
Q24302024Synaptic vesicle trafficking and Parkinson's disease
Q34109658Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms
Q48125960TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains.
Q41867906Targeting the low-hanging fruit of neurodegeneration
Q38024715The "Janus-faced role" of autophagy in neuronal sickness: focus on neurodegeneration
Q30357944The Monoamine Brainstem Reticular Formation as a Paradigm for Re-Defining Various Phenotypes of Parkinson's Disease Owing Genetic and Anatomical Specificity.
Q26822972The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases
Q40202718The Potential Mutation of GAK Gene in the Typical Sporadic Parkinson's Disease from the Han Population of Chinese Mainland.
Q52327330The Retromer Complex and Sorting Nexins in Neurodegenerative Diseases.
Q38026044The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease
Q38482479The Role of α-Synuclein and LRRK2 in Tau Phosphorylation
Q38093808The VPS35 gene and Parkinson's disease
Q37369346The association between Parkinson's disease and anti-epilepsy drug carbamazepine: a case-control study using the UK General Practice Research Database
Q37845675The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease
Q38998036The effects of morphine on Parkinson's-related genes PINK1 and PARK2.
Q34557246The endotoxin-induced neuroinflammation model of Parkinson's disease.
Q47646796The genetic architecture of mitochondrial dysfunction in Parkinson's disease
Q34513714The genetic background of Parkinson's disease: current progress and future prospects
Q34604083The genetics of Parkinson disease
Q28543195The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease
Q37111847The mitochondrial dynamics of Alzheimer's disease and Parkinson's disease offer important opportunities for therapeutic intervention
Q28117293The parkin-like human homolog of Drosophila ariadne-1 (HHARI) can induce aggresome formation in mammalian cells and is immunologically detectable in Lewy bodies
Q28077257The relationship between glucocerebrosidase mutations and Parkinson disease
Q37646362The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease
Q38166155The role of innate and adaptive immunity in Parkinson's disease
Q38290759Therapeutic strategies in Parkinson's disease: what we have learned from animal models
Q39273083Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease
Q33614776Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease
Q37897498Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system
Q42173591Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination
Q39067542Ultrasound-based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers
Q37555526Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions
Q37896718Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders
Q35008102Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts
Q92824874VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease
Q50254001VPS35 mutation in Japanese patients with typical Parkinson's disease
Q35327512Vitamin D from different sources is inversely associated with Parkinson disease
Q36315569Whole genome expression profile in neuroblastoma cells exposed to 1-methyl-4-phenylpyridine
Q28771729Widespread macromolecular interaction perturbations in human genetic disorders
Q44012668YY1 binds to α-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression.
Q38247942Zinc Finger Nucleases: A new era for transgenic animals
Q38742153α-Synuclein and Parkinsonism: Updates and Future Perspectives
Q64866429α-Synuclein and Polyunsaturated Fatty Acids: Molecular Basis of the Interaction and Implication in Neurodegeneration
Q35100189α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease
Q38912683α-Synuclein-carrying extracellular vesicles in Parkinson's disease: deadly transmitters
Q84539110β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease